On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Johnson & Johnson’s Spravato gains FDA approval for standalone depression treatment ahead of Q4 earnings. JNJ stock shows short-term bullish signals, but long-term trends remain bearish ahead of ...
Add Yahoo as a preferred source to see more of our stories on Google. An estimated 21 million American adults suffer from clinical depression. (Getty Images) Major depressive disorder affects an ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results